Neoplasms by Histologic Type Clinical Trial
Official title:
A PHASE I TRIAL OF PF-03084014 IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCY AND T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA
This is a phase 1, dose escalating study to determine the safety of PF-03084014 in patients with advanced cancer and leukemia
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01234480 -
Intended Use Study of the BD SurePath Plus™ Pap
|
||
| Completed |
NCT02909452 -
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT03911388 -
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
|
Phase 1 | |
| Recruiting |
NCT04566952 -
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
|
Phase 2 | |
| Recruiting |
NCT05770102 -
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
|
Phase 2/Phase 3 | |
| Terminated |
NCT02543645 -
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT01037049 -
Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks
|
Phase 2 | |
| Recruiting |
NCT04556071 -
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT03744676 -
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
|
Phase 2 | |
| Suspended |
NCT03722186 -
Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT05298683 -
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
|
Phase 2 | |
| Terminated |
NCT02386111 -
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
|
Phase 1 | |
| Not yet recruiting |
NCT01556815 -
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT05186558 -
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
|
Phase 2 | |
| Active, not recruiting |
NCT04309084 -
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT04949282 -
Spanish Series of Patients Treated With the Radionuclide Lutetium177
|
||
| Active, not recruiting |
NCT05241873 -
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
|
Phase 1/Phase 2 | |
| Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04310592 -
Natural Killer Cell (CYNK-001) Infusions in Adults With AML
|
Phase 1 | |
| Recruiting |
NCT04124198 -
Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma
|
N/A |